Breast Cancer, Lung Cancer, Prostate Cancer
Conditions
Keywords
Breast, Lung, Prostate, Vaccine
Brief summary
Infections due to influenza and pneumococcus can be very serious and cause death. Anyone can get these infections. However, some people are at greater risk from the disease, including people 65 and older, the very young, and people with special health problems such as people with certain types of cancer, heart, lung, or kidney disease, or diabetes. Influenza can cause a very serious lung infection (pneumonia) and increase the risk of stroke and heart attacks. Pneumococcal disease can lead to serious infections in the lungs (pneumonia), the blood (bacteremia), and the covering of the brain (meningitis). People with the special health problems mentioned above are even more likely to die from the disease. Although there are drugs to treat these infections, they are not always effective. This makes prevention of the disease through vaccination even more important. This study will look at the body's response to influenza and pneumococcal vaccination. We want to see how well they it will protect. Immunization is the same as vaccination. Our goal is to protect as much as we can. We are doing the study because more information is needed to see how well older patients with cancer respond to these vaccines and how well they protect against disease caused by influenza and pneumococcus.
Interventions
BIOLOGICALinactivated influenza vaccine and the 23- valent pneumococcal vaccine
Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
BIOLOGICALinactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient must be \> or = to 65 years of age. * Patient may be an in patient or an out-patient. * Patient must have a diagnosis of prostate, lung, or breast cancer. * Patient must have a life expectancy of \> or = to 6 months. * Patient must have a Karnofsky score of \>40% * Patient must be willing to return to the hospital in 8-12 weeks following immunization for blood work. * Patients must have a platelet count of \>75,000 for intramuscular injection. * Patient may be of either gender and of any ethnic background. * Patients must be able to understand the nature and risk of the proposed study and be able to sign consent. Volunteer eligibility: * MSKCC employee * Age \> or = to 65 years of age * No previous diagnosis of cancer except basal cell carcinoma, resected Stage I melanoma or in situ cervical carcinoma. Volunteers may have had a prior history of other cancers \> 3 years which required only local resection, local radiation and/or hormonal therapy such as androgen blockade. * Patients must be able to understand the nature and risk of the proposed study and be able to sign consent.
Exclusion criteria
* Karnofsky score \<40%: * Patients who have received an autologous or allogeneic HCT * Active uncontrolled bacterial or fungal infection * Hypersensitivity to egg protein (eggs or egg products), chicken proteins, or any component in the influenza vaccine * Prior history of any life-threatening reaction after previous administration of any influenza vaccine or any component such as thimerosal (inclusion of thimerosal varies among packaging) * Latex allergy if going to receive the influenza vaccine * On-going neurologic disorder (mental status change, uncontrolled seizures, encephalopathy) * Treatment or planned treatment with cyclophosphamide, ifosphamide, or \> or = to 1 mg/kg prednisone or its equivalent 12 weeks within 12 weeks of vaccination. * HIV-1,2 seropositive patients. * Patients not signing informed consent. * Patients receiving the seasonal influenza vaccine may not have had it within 6 months of enrollment Healthy controls exclusion: * Volunteers ineligible to receive either vaccine * Volunteers unwilling or unable to sign consent * Hypersensitivity to egg protein (eggs or egg products), chicken proteins, or any component in the influenza vaccine * Latex allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine Response Rate of Patients > or = to 65 Yrs Diagnosed | 8-16 weeks following vaccination. | For Pneumovax, complete response will be either seroconversion or a \>3 fold rise in titer against at least 5 of the following serotypes contained in Pneumovax (serotypes 4, 14, 19, 23, 6B, 18C, and 9V). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Adult Cancer Patients 65 Years of Age and Older Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | 102 |
| Healthy Volunteers Vaccine Responses Against Pneumococcus and Influenza in Adults 65 Years of Age and Older | 25 |
| Total | 127 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Patient non-compliance | 2 | 0 |
Baseline characteristics
| Characteristic | Adult Cancer Patients 65 Years of Age and Older | Healthy Volunteers | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 99 Participants | 25 Participants | 124 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 0 Participants | 3 Participants |
| Sex: Female, Male Female | 60 Participants | 13 Participants | 73 Participants |
| Sex: Female, Male Male | 42 Participants | 12 Participants | 54 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 95 | 0 / 25 |
| serious Total, serious adverse events | 0 / 95 | 0 / 25 |
Outcome results
Primary
Determine Response Rate of Patients > or = to 65 Yrs Diagnosed
For Pneumovax, complete response will be either seroconversion or a \>3 fold rise in titer against at least 5 of the following serotypes contained in Pneumovax (serotypes 4, 14, 19, 23, 6B, 18C, and 9V).
Time frame: 8-16 weeks following vaccination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Adult Cancer Patients 65 Years of Age and Older | Determine Response Rate of Patients > or = to 65 Yrs Diagnosed | 63 participants |
| Healthy Volunteers | Determine Response Rate of Patients > or = to 65 Yrs Diagnosed | 24 participants |